Chronic Eye Diseases: Exploring Sustained-Release Treatments
Media formats available:
Details
Presenters
Overview
Supported by an educational grant from Allergan and EyePoint Pharmaceuticals. Learning Objectives
Upon completion of this activity, the participant should be able to: - Assess data from the latest clinical studies on sustained-release devices and methods.
- Describe the benefits and challenges of sustained-release devices and methods versus conventional treatments.
- Identify the various sustained-release devices on the market and in the pipeline.
- Evaluate how to incorporate sustained-release devices into treatment regimens.
Accreditation
Accreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participation Method
To obtain AMA PRA Category 1 Credit™ for this activity, you must read the activity in its entirety and complete the Pretest/Posttest/Activity Evaluation/Satisfaction Measures Form, which consists of a series of multiple-choice questions. Faculty and Disclosures
DISCLOSURE POLICY
The following faculty/staff members have the following financial relationships with commercial interests: Thomas A. Albini, MD Dr. Albini has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Speaker’s Bureau/Grant/Research/Support: Alimera, Allergan, Bausch + Lomb, Eyepoint, Genentech, and Regenexbio. Alimera, Allergan, Bausch + Lomb, Eyepoint, Genentech, Regenexbio; Investigator in MUST and MACTEL study. Nathan M. Radcliffe, MD Dr. Radcliffe has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Alcon, Alimera, Allergan, Bausch & Lomb, Ellex, Endo Optiks, Equinox Glaukos Reichert, Iridex, Lumenis, New World Medical, Novartis, and Sight Sciences. Speaker’s Bureau: Aerie, Alcon, Alimera Allergan, Bausch & Lomb, Carl Zeiss Meditec, CATS Ellex, Endo Optiks, Equinox, Eyenovia, Eyepoint, Glaukos, Iridex, Ivantis, Lumenis, New World Medical, Novartis Ocular Science Omeros, Reichert, Sight Sciences, Shire, Thea, Pharmaceuticals Editorial Support Disclosures Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
Off-Label Statement This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Allergan, or EyePoint Pharmaceuticals. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!